Drugs / Mibavademab
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03530514 | Apr 2018 → Jan 2020 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT07235917 | Mar 2026 → Jan 2028 expected | functional hypothalamic amenorrhea | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT06373146 | Apr 2024 → Dec 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT05088460 | Feb 2022 → Dec 2023 | familial partial lipodystrophy | Regeneron Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04159415 | Jan 2020 → Jan 2022 | generalized lipodystrophy | Regeneron Pharmaceuticals | Completed | Missed primary |
| Phase 33 trials | ||||||
| Phase 3 | NCT07220785 | Mar 2026 → May 2028 expected | generalized lipodystrophy | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT07220772 | Feb 2026 → Jun 2027 expected | obesity due to congenital leptin deficiency | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06548100 | Dec 2024 → Jul 2026 overdue | generalized lipodystrophy | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04710056 | — | generalized lipodystrophy, inherited obesity | Regeneron Pharmaceuticals | Available | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mibavademab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07220772 ↗ |
| Known as | REGN4461 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04159415 ↗ |
| Action | Activate | “Leptin Receptor Agonist Antibody” NCT04159415 ↗1“Leptin receptor agonist” CHEMBL4650509 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4650509 ↗ |
| Route | Intravenous | “intravenous (IV)” NCT03530514 ↗ |
| Target | LEPR | “Leptin receptor agonist” CHEMBL4650509 ↗ |